Literature DB >> 4005393

Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: a single dose study.

R Zaman, D B Jack, M R Wilkins, M J Kendall.   

Abstract

The pharmacokinetics of acebutolol and its major metabolite, diacetolol, following a single 400 mg oral dose, were investigated in patients with liver disease. No significant differences were found in any of the parameters measured.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005393     DOI: 10.1002/bdd.2510060204

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  4 in total

Review 1.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

Review 2.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

3.  Liver abnormalities in cardiac diseases and heart failure.

Authors:  Alicia M Alvarez; Debabrata Mukherjee
Journal:  Int J Angiol       Date:  2011-09

Review 4.  From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?

Authors:  Anna Sessa; Manon Allaire; Pascal Lebray; Mourad Medmoun; Alberto Tiritilli; Pierre Iaria; Jean-François Cadranel
Journal:  JHEP Rep       Date:  2021-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.